TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Tumor antigens are crucial for cancer diagnosis, prognosis, and targeted therapy.
• Advances in cancer genomics enable the identification of tumor-specific neoantigens, vital for cancer immunotherapy.
• Developing user-friendly tools is essential for translating genomic discoveries into clinical applications.

Purpose of the Study:

• To develop a software tool, the tumor-specific neoantigen detector (tsnad).
• To detect cancer somatic mutations and predict potential tumor-specific neoantigens.
• To provide a bioinformatics pipeline accessible to biologists with limited programming experience.

Main Methods:

• The tumor-specific neoantigen detector (tsnad) software was developed.
• It follows best practices from the genome analysis toolkit for mutation detection.
• It predicts neoantigens from extracellular mutations of membrane proteins or mutated peptides presented by MHC class I molecules.

Main Results:

• The software successfully detected cancer somatic mutations.
• Numerous potential tumor-specific neoantigens were predicted using the software.
• The pipeline was applied to somatic mutation data from the International Cancer Genome Consortium database.

Conclusions:

• The developed software facilitates the identification of tumor-specific neoantigens.
• This tool supports cancer immunotherapy research by simplifying neoantigen prediction.
• The software is freely available, promoting wider adoption in cancer research.